Skip to main content

Advertisement

SpringerLink
Log in

Polyvalent immunoglobulin for intravenous use interferes with cell proliferationin vitro

  • Original Articles
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Intravenous immunoglobulin is used to an increasing extent in various immune-mediated diseases, but its mechanism(s) of actionin vivo is incompletely understood. Previous studies have shown that intravenous immunoglobulin may interfere with autoantibodies and their production by B cells and also inhibit Fc-mediated antibody-dependent cytotoxicity. Here we describe a novel effect of intravenous immunoglobulin on proliferation ofin vitro activated peripheral blood lymphocytes and autonomously growing cell lines of various origin. Independently of whether proliferation was autonomous or induced by antigen-specific or antigen-nonspecific reagents, proliferation was inhibited in a dose-dependent fashion, as measured by reduced3H-thymidine and BrdU uptake and cell counting. The effect was not due to cytotoxic effects of intravenous immunoglobulin and was reversible after removing the intravenous immunoglobulin by washing. The IgG levels required for this inhibition of proliferation are supraphysiological but are reachedin vivo during treatment with intravenous immunoglobulin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Imbach P, d'Apuzzo V, Hirt A, Rossi E, Vest M, Barandun S, Baumgartner C, Morell A, Schoni M, Wagner HP: Highdose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1230, 1981

    Google Scholar 

  2. Buckley RH, Schiff RI: Drug therapy: The use of intravenous immunoglobulin in immunodeficiency diseases. N Engl J Med 325:110–117, 1991

    Google Scholar 

  3. Berkman SA, Lee ML, Gale RP: Clinical uses of intravenous immunoglobulins. Ann Intern Med 112:278–292, 1990

    Google Scholar 

  4. Dwyer JM: Intravenous therapy with gamma globulin. Adv Intern Med 32:111–136, 1987

    Google Scholar 

  5. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Petersen FB, Witherspoon RP, Budinger MD, Schwartz RS, Appelbaum FR, Clift RA, Hansen JA, Sanders JE, Thomas ED, Storb R: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705–712, 1990

    Google Scholar 

  6. Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137–1139, 1991

    Google Scholar 

  7. Sultan Y, Rossi F, Kazatchkine MD: Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci 84:828–831, 1987

    Google Scholar 

  8. McGuire WA, Yang HH, Bruno E, Brandt J, Briddell R, Coates TD, Hoffman R: Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 317:1004–1008, 1987

    Google Scholar 

  9. Brand A, Witvliet M, Claas FHJ, Eernisse JG: Beneficial effect of intravenous gammaglobulin in a patient with complement-mediated autoimmune thrombocytopenia due to IgM-anti-platelet antibodies. Br J Haematol 70:1–5, 1988

    Google Scholar 

  10. Doorn PA van, Rossi F, Brand A, Lint M van, Vermeulen M, Kazatchkine MD: On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 29:57–64, 1990

    Google Scholar 

  11. Lundkvist I, Doorn PA van, Vermeulen M, Lint M van, Rood JJ van, Brand A: Regulation of autoantibodies in inflammatory demyelinating polyneuropathy: Spontaneous and therapeutic. Immunol Rev 110:105–117, 1989

    Google Scholar 

  12. Fehr J, Hoffman V, Kappeler U: Transient reversal of trombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306:1254–1258, 1982

    Google Scholar 

  13. Leung DYM, Burns JC, Newburger JW, Geha RS: Reversal of lymphocyte activation in vivo in the kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 79:468–472, 1987

    Google Scholar 

  14. Macey MG, Newland AC: CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Haematol 76:513–520, 1990

    Google Scholar 

  15. Tsubakio T, Kurata Y, Katagiri S, Kanakuru T, Tamaki T, Kuyama J, Kanayama Y, Yoneza T, Tarui S: Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 53:697–702, 1983

    Google Scholar 

  16. Delfraissy JF, Tchernia G, Laurian Y, Wallon C, Galanaud P, Dormont J: Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol 60:315–322, 1985

    Google Scholar 

  17. Dietrich G, Pereira P, Algiman M, Sultan Y, Kazatchkine MD: A Monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines an idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmun 3:547–557, 1990

    Google Scholar 

  18. Hashimoto F, Sakiyama Y, Matsumoto S: The suppressive effect of gammaglobulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. Clin Exp Immunol 65:409–415, 1986

    Google Scholar 

  19. Stohl W: Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 136:4407–4413, 1986

    Google Scholar 

  20. Kondo N, Ozawa T, Mushiake K, Motoyoshi F, Kameyama T, Kasahara K, Kaneko H, Yamashina M, Kato Y, Orii T: Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 11:152–158, 1991

    Google Scholar 

  21. Jungi TW, Santer M, Lerch PG, Barandun S: Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte receptors. A comparative study. Vox Sang 51:18–26, 1986

    Google Scholar 

  22. Kurlander RJ: Reversible and irreversible loss of receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 66:773–781, 1980

    Google Scholar 

  23. Saleh M, Court W, Huster W, Shaw D, Lobuglio A: Effect of commercial immunoglobulin G preparation on human monocyte-receptor dependent binding of antibody coated platelets. Br J Haematol 68:47–51, 1988

    Google Scholar 

  24. Engelhard D, Warner JL, Kapoor N, Good RA: Effect of intravenous immunoglobulin on natural killer cell activity: Possible association with autoimmune neutropenia and idiopathic trombocytopenia. J Pediat 108:77–81, 1986

    Google Scholar 

  25. Kawada K, Terasaki PI: Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol 15:133–136, 1987

    Google Scholar 

  26. Äkerström B, Brodin T, Reis K, Björk L: Protein G: A powerful tool for binding and detection of monoclonal and polyclonal antibodies. J Immunol 135:2589–2592, 1985

    Google Scholar 

  27. Palacios R: Mechanism of T-cell activation: Role and functional relationship of HLA-DR antigens and interleukins. Immunol Rev 63:73–110, 1982

    Google Scholar 

  28. Hodge JW, Wust CJ, Ichiki AT, Lozzio CB: Antibodies to specific cell surface antigens of a human leukemia cell line, K 562, transduce negative growth signals.In Annals of the New York Academy of Sciences, A Anagnostou, N Dainiak, A Najman (eds). New York, New York Academy of Sciences, 1991, pp 165–168

    Google Scholar 

  29. Shapiro RS, Chauvenet A, McGuire W, Pearson A, Craft AW, McGlave P, Filipovich A: Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med 318:1334, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunohematology and Bloodbank, E3-Q42, University Hospital Leiden, P.O. Box 9600, 2300 RC, Leiden, the Netherlands

    I. N. van Schaik & A. Brand

  2. Department of Clinical Immunology, Karolinska Institute, Huddinge, Sweden

    I. Lundkvist

  3. Department of Neurology, Academical Medical Center, Amsterdam, the Netherlands

    M. Vermeulen

Authors
  1. I. N. van Schaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Lundkvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Vermeulen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Brand
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Schaik, I.N., Lundkvist, I., Vermeulen, M. et al. Polyvalent immunoglobulin for intravenous use interferes with cell proliferationin vitro . J Clin Immunol 12, 325–334 (1992). https://doi.org/10.1007/BF00920789

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00920789

Key words

Search

Navigation